A prognostic value of syndecan-1 in gastric cancer.
A prognostic value of syndecan-1 in gastric cancer.
复制标题
Syndecan-1 在胃癌中的预后价值。
作者：
J. Wiksten;J. Lundin;S. Nordling;A. Kokkola;C. Haglund
背景
Syndecan-1是一种细胞表面硫酸乙酰肝素蛋白聚糖，在细胞粘附、成熟和增殖中起作用。据报道，多配体蛋白聚糖-1在各种癌症形式中是有希望的预后标志物。
材料和方法
我们分析了296例胃癌患者的肿瘤标本。免疫组化法检测Syndecan-1的表达。
结果
在234例（79%）患者中观察到Syndecan-1免疫反应性。syndecan-1的表达与淋巴结转移、远处转移、腹膜扩散、穿透深度、肿瘤大小、肿瘤位置、Borrmann分类、Laurén分类、年龄或性别无关。Syndecan-1免疫反应性与整个患者系列（p = 0.0499）和I期癌症患者亚组（p = 0.0417）的生存率显著相关，但与II、III或IV期疾病患者无关。在多变量生存分析中，疾病分期和肿瘤大小是唯一的独立预后因素。
结论
总之，syndecan-1的免疫组化表达是胃癌的一个潜在的预后因素，特别是在I期疾病的患者。
BACKGROUND
Syndecan-1, a cell surface heparan sulphate proteoglycan, has a role in cell adhesion, maturation and proliferation. Syndecan-1 has been reported to be a promising prognostic marker in various cancer forms.
MATERIALS AND METHODS
We analysed tumour specimens from 296 gastric cancer patients. Syndecan-1 expression was studied by immunohistochemistry.
RESULTS
Syndecan-1 immunoreactivity was observed in 234 (79%) patients. The expression of syndecan-1 did not correlate significantly with the presence of lymph node metastases, distant metastases, peritoneal spreading, penetration depth, tumour size, tumour location, Borrmann's classification, Laurén's classification, age or gender. Syndecan-1 immunoreactivity correlated significantly with survival in the whole patient series (p = 0.0499) and also in the subgroup of patients with stage I cancer (p = 0.0417), but not in patients with stage II, III or IV disease. In multivariate survival analysis, stage of disease and tumour size emerged as the only independent prognostic factors.
CONCLUSIONS
In conclusion, immunohistochemical expression of syndecan-1 is a potential prognostic factor in gastric cancer, especially in patients with stage I disease.